Hikma intros hydralazine hydrochloride
Hydralazine hydrochloride injection had a market value of roughly $51 million in the 12 months ended March 2021, according to IQVIA.
Hikma is offering hydralazine hydrochloride injection, in a dosage strength of 20mg/mL.
The medication is indicated for severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
Hydralazine hydrochloride injection had a market value of approximately $51 million in the 12 months ended March 2021, according to IQVIA.